In this episode, Rick Eiswirth, president and CEO of Alimera Sciences, shares the latest on the phase 4 New Day study of Iluvien, as well as his predictions for the future of ophthalmology.

• Intro :13
• In this episode :18
• About Rick Eiswirth :23
• What’s your background? How did you get into the ophthalmology industry? 0:51
• What are the benefits of Iluvien (fluocinolone acetonide intravitreal implant, Alimera Sciences)? Is this an ideal treatment for 2021? 3:36
• How do you get retina specialists more onboard with using intravitreal steroids earlier, given anti-VEGFs’ predominance? 6:26
• Can you tell us more about the New Day trial? 8:10
• Which trial outcome would be considered a success for Iluvien? 11:58
• Do you anticipate a cost savings? 13:58
• What’s the status of the New Day trial? 15:15
• How has COVID changed the industry landscape in ophthalmology? 16:20
• Are there any new products in the pipeline? 18:38
• Iluvien is approved in other countries for uveitis 20:36
• What have you seen from retina specialists; are there longer efficacy rates? 22:10
• What do you think is the most important challenge the ophthalmic community will face in the future? 23:17
• Thanks for listening 24:36

Rick Eiswirth is president and CEO of Alimera Sciences.

We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN.

Disclosures: Eiswirth is president and CEO of Alimera Sciences. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.